Anti-Human IL 12/23 (Briakinumab) – Biotin
Anti-Human IL 12/23 (Briakinumab) – Biotin
Product No.: LT501
- -
- -
Product No.LT501 Clone ABT-874 Target IL-12/IL-23 p40 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23 Isotype Human IgG1λ Applications ELISA , FA , FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen This antibody was produced by phage display technology. Product Concentration 0.5 mg/ml Formulation This Biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This biotinylated antibody is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2893963 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. ELISA Additional Applications Reported In Literature ? FA Additional Reported Applications For Relevant Conjugates ? B N WB IF IP Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only. Background Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Antigen Distribution IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars References & Citations1. Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123 Technical Protocols FA  Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT500 | |
LT504 | |
LT502 | |
LT501 | |
LT511 | |
LT506 | |
LT505 | |
LT507 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.